|
|
 Previous Article | Table of Contents | Next Article 
High Level Engraftment of NOD/SCID Mice by Primitive Normal and
Leukemic Hematopoietic Cells From Patients With Chronic Myeloid
Leukemia in Chronic Phase
J.C.Y. Wang,
T. Lapidot,
J.D. Cashman,
M. Doedens,
L. Addy,
D.R. Sutherland,
R. Nayar,
P. Laraya,
M. Minden,
A. Keating,
A.C. Eaves,
C.J. Eaves, and
J.E. Dick
From the Department of Genetics, Research Institute, Hospital for
Sick Children; the Department of Molecular and Medical Genetics,
University of Toronto; the Department of Medicine, Princess Margaret
Hospital; the Department of Hematology/Oncology, the Toronto Hospital,
Toronto, Ontario; and the Terry Fox Laboratory, British Columbia Cancer
Agency, Vancouver, British Columbia, Canada.
We have previously shown that intravenously injected peripheral
blood (PB) or bone marrow (BM) cells from newly diagnosed chronic
myeloid leukemia (CML) patients can engraft the BM of sublethally
irradiated severe combined immunodeficient (SCID) mice. We now report
engraftment results for chronic phase CML cells in nonobese diabetic
(NOD)/SCID recipients which show the superiority of this latter model.
Transplantation of NOD/SCID mice with 7 to 10 × 107 patient PB or BM cells resulted in the continuing
presence of human cells in the BM of the mice for up to 7 months, and
primitive human CD34+ cells, including those detectable
as colony-forming cells (CFC), as long-term culture-initiating cells,
or by their coexpression of Thy-1, were found in a higher proportion of
the NOD/SCID recipients analyzed, and at higher levels than were seen
previously in SCID recipients. The human CFC and total human cells
present in the BM of the NOD/SCID mice transplanted with CML cells also
contained higher proportions of leukemic cells than were obtained in
the SCID model, and NOD/SCID mice could be repopulated with transplants of enriched CD34+ cells from patients with CML. These
results suggest that the NOD/SCID mouse may allow greater engraftment
and amplification of both normal and leukemic (Ph+)
cells sufficient for the quantitation and characterization of the
normal and leukemic stem cells present in patients with CML. In
addition, this model should make practical the investigation of
mechanisms underlying progression of the disease and the development of
more effective in vivo therapies.
Blood, Vol. 91 No. 7 (April 1), 1998:
pp. 2406-2414
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. V. Cox, P. Diamanti, R. S. Evely, P. R. Kearns, and A. Blair
Expression of CD133 on leukemia-initiating cells in childhood ALL
Blood,
April 2, 2009;
113(14):
3287 - 3296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Shackleton, E. Quintana, D. R. Fullen, M. S. Sabel, and T. M. Johnson
Melanoma: Do We Need a Hatchet or a Scalpel?
Arch Dermatol,
March 1, 2009;
145(3):
307 - 308.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kavalerchik, D. Goff, and C. H.M. Jamieson
Chronic Myeloid Leukemia Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2911 - 2915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Fang, C. Zheng, L. Liao, Q. Han, Z. Sun, X. Jiang, and R. C. H. Zhao
Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics
Blood,
April 1, 2005;
105(7):
2733 - 2740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Xu, E. Bruno, J. Chao, H. Ni, V. Lindgren, R. Nunez, N. Mahmud, G. Finazzi, S. M. Fruchtman, U. Popat, et al.
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis
Blood,
February 15, 2005;
105(4):
1699 - 1705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Thanopoulou, J. Cashman, T. Kakagianne, A. Eaves, N. Zoumbos, and C. Eaves
Engraftment of NOD/SCID-{beta}2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome
Blood,
June 1, 2004;
103(11):
4285 - 4293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. M. Liem, R. A. Papa, C. G. Milross, M. A. Schmid, M. Tajbakhsh, S. Choi, C. D. Ramirez, A. M. Rice, M. Haber, M. D. Norris, et al.
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
Blood,
May 15, 2004;
103(10):
3905 - 3914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bruno, M. Gunetti, L. Gammaitoni, E. Perissinotto, L. Caione, F. Sanavio, F. Fagioli, M. Aglietta, and W. Piacibello
Fast But Durable Megakaryocyte Repopulation and Platelet Production in NOD/SCID Mice Transplanted with Ex-Vivo Expanded Human Cord Blood CD34+ Cells
Stem Cells,
March 1, 2004;
22(2):
135 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-Y. Huang, H.-F. Tien, F.-H. Su, and S.-M. Hsu
Nonirradiated NOD/SCID-Human Chimeric Animal Model for Primary Human Multiple Myeloma: A Potential in Vivo Culture System
Am. J. Pathol.,
February 1, 2004;
164(2):
747 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Lock, N. Liem, M. L. Farnsworth, C. G. Milross, C. Xue, M. Tajbakhsh, M. Haber, M. D. Norris, G. M. Marshall, and A. M. Rice
The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse
Blood,
May 13, 2002;
99(11):
4100 - 4108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Peled, I. Hardan, L. Trakhtenbrot, E. Gur, M. Magid, M. Darash-Yahana, N. Cohen, V. Grabovsky, S. Franitza, O. Kollet, et al.
Immature Leukemic CD34+CXCR4+ Cells from CML Patients Have Lower Integrin-Dependent Migration and Adhesion in Response to the Chemokine SDF-1
Stem Cells,
May 1, 2002;
20(3):
259 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Zhao, Y. Jiang, and C. M. Verfaillie
A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector
Blood,
April 15, 2001;
97(8):
2406 - 2412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood,
February 1, 2001;
97(3):
720 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gao, I. Bellantuono, A. Elsasser, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
Blood,
April 1, 2000;
95(7):
2198 - 2203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Brummendorf, T. L. Holyoake, N. Rufer, M. J. Barnett, M. Schulzer, C. J. Eaves, A. C. Eaves, and P. M. Lansdorp
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Blood,
March 15, 2000;
95(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Honda, T. Ushijima, K. Wakazono, H. Oda, Y. Tanaka, S.-i. Aizawa, T. Ishikawa, Y. Yazaki, and H. Hirai
Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CML
Blood,
February 15, 2000;
95(4):
1144 - 1150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
PNAS,
October 26, 1999;
96(22):
12804 - 12809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Holyoake, X. Jiang, C. Eaves, and A. Eaves
Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia
Blood,
September 15, 1999;
94(6):
2056 - 2064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Ailles, B. Gerhard, H. Kawagoe, and D. E. Hogge
Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice
Blood,
September 1, 1999;
94(5):
1761 - 1772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. le Coutre, L. Mologni, L. Cleris, E. Marchesi, E. Buchdunger, R. Giardini, F. Formelli, and C. Gambacorti-Passerini
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
J Natl Cancer Inst,
January 20, 1999;
91(2):
163 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hoyle, C. D. Bangs, P. Chang, O. Kamel, B. Mehta, and R. S. Negrin
Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice
Blood,
November 1, 1998;
92(9):
3318 - 3327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
